Hypothesis

Aging‑associated collagen fragments suppress ERK/ELK‑1 signaling, leading to recruitment of DNA methyltransferases to the HAS2 promoter and stable epigenetic silencing that persists even when fragment levels fall.

Mechanistic Model

• Collagen fragments accumulate in aged dermis → inhibit nuclear ERK1/2 translocation and ELK‑1 phosphorylation Collagen fragments reduce nuclear accumulation of phospho-ERK1/2 and phosphorylation of ELK-1, reducing HAS2 expression.
• Reduced ERK/ELK‑1 activity diminishes phosphorylation of downstream co‑activators (e.g., MSK1) that normally protect CpG islands from de novo methylation.
• Unprotected HAS2 promoter CpG islands become substrates for DNMT3A/3B, establishing methylated chromatin that blocks transcription irrespective of ERK status.
• Methylated HAS2 sustains low HMW‑HA synthesis, shifting the HA pool toward LMW‑HA fragments that act as DAMPs via TLR2/TLR4 Oligosaccharide HA activates TLR2/TLR4 in synovial fibroblasts without CD44 involvement.
• LMW‑HA‑driven NF‑κB signaling further up‑regulates MMPs, generating more collagen fragments, completing a self‑reinforcing loop.

Testable Predictions

1. In fibroblasts from donors >65 yr, the HAS2 promoter will show higher CpG methylation than in <30 yr cells, correlating with low ERK‑dependent ELK‑1 phosphorylation.
2. Pharmacological inhibition of DNMTs (e.g., 5-aza-2'-deoxycytidine) in aged fibroblasts will restore ERK‑independent HAS2 transcription and HMW‑HA secretion.
3. CRISPR‑dCas9‑TET1 targeted demethylation of the HAS2 promoter in aged fibroblasts will rescue HMW‑HA production even when ERK/ELK‑1 signaling remains suppressed.
4. Mice expressing a fibroblast‑specific, methylation‑resistant HAS2 promoter (CpG‑mutated) will resist age‑related HA fragmentation and display reduced dermal inflammation despite elevated collagen fragments.

Experimental Approach

• Human fibroblasts: isolate from young and old donors, measure p‑ERK1/2 nuclear levels, ELK‑1 phosphorylation, HAS2 mRNA, HA size distribution (SEC‑MALS), and bisulfite sequencing of the HAS2 promoter.
• Epigenetic rescue: treat aged fibroblasts with DNMT inhibitor or CRISPR‑dCas9‑TET1; assess HAS2 expression and HA synthesis.
• In vivo validation: generate knock‑in mice with a fibroblast‑specific HAS2 promoter lacking CpG sites; challenge with induced collagen fragmentation (e.g., subcutaneous injection of collagenase) and evaluate HA molecular weight, CD44 clustering, and inflammatory cytokines.

Therapeutic Implication

If epigenetic silencing is the dominant brake on HAS2 in aging skin, therapies that demethylate or protect the HAS2 locus (small‑molecule DNMT inhibitors, targeted epigenetic editors, or gene‑editing approaches) could restore endogenous HMW‑HA production more effectively than exogenous HA supplementation, breaking the collagen‑fragment/HAS2/LMW‑HA inflammatory circuit.